Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2 / GBA mutated Parkinson's disease
CNS Neuroscience & Therapeutics · 2024-06 · 30 (6)
DOI: 10.1111/cns.14728 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 04.06.2024. Verfasst von Fabin Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center for Cognitive Neurology, Institute of Clinical Neurology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Prodromal Symptoms, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Province Joint Funds for the Innovation of Science and Technology, Clinical Key Specialty of Fujian Province (Neurology).
Abstract (Originalsprache)
Introduction
Prodromal Parkinson's disease (PD) carriers of dual leucine‐rich repeat kinase 2 (LRRK2) and glucosylceramidase β (GBA) variants are rare, and their biomarkers are less well developed.
Objective
This study aimed to investigate the biomarkers for diagnosing the prodromal phase of LRRK2‐GBA‐PD (LRRK2‐GBA‐prodromal).
Methods
We assessed the clinical and whole‐brain white matter microstructural characteristics of 54 prodromal PD carriers of dual LRRK2 (100% M239T) and GBA (95% N409S) variants, along with 76 healthy controls (HCs) from the Parkinson's Progression Markers Initiative (PPMI) cohort.
Results
By analyzing the four values of 100 nodes on 20 fiber bundles, totaling 8000 data points, we identified the smallest p value in the fractional anisotropy (FA) value of the 38th segment of left corticospinal tract (L‐CST) with differences between LRRK2‐GBA‐prodromal and HCs ( p = 8.94 × 10 −9 ). The FA value of the 38th node of the L‐CST was significantly lower in LRRK2‐GBA‐prodromal (FA value, 0.65) compared with HCs (FA value, 0.71). The receiver‐operating characteristic curve showed a cut‐off value of 0.218 for the FA value of L‐CST, providing sufficient sensitivity (79.2%) and specificity (72.2%) to distinguish double mutation prodromal PD from the healthy population.
Conclusion
L‐CST, especially the 38th node, may potentially serve as a biomarker for distinguishing individuals with double mutation prodromal PD from the healthy population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Center for Cognitive Neurology, Institute of Clinical Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
- Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, China.
- Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
- Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, China.
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Fabin Lin, Fangang Meng, Guoen Cai
Förderung
- Fujian Province Joint Funds for the Innovation of Science and Technology
- Clinical Key Specialty of Fujian Province (Neurology)
Zitieren
APA
Lin, F., Ruan, X., Zou, X., Weng, H., Zeng, Y., Zheng, J., Ye, Q., Meng, F., Chen, X., & Cai, G. (2024). Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2 / GBA mutated Parkinson's disease. CNS Neuroscience & Therapeutics, 30(6). https://doi.org/10.1111/cns.14728
Vancouver
Lin F, Ruan X, Zou X, Weng H, Zeng Y, Zheng J, et al. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2 / GBA mutated Parkinson's disease. CNS Neuroscience & Therapeutics. 2024;30(6). doi:10.1111/cns.14728
BibTeX
@article{Lin2024,
author = {Lin, Fabin and Ruan, Xinlin and Zou, Xinyang and Weng, Huidan and Zeng, Yuqi and Zheng, Jiayi and Ye, Qinyong and Meng, Fangang and Chen, Xiaochun and Cai, Guoen},
title = {Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2 / GBA mutated Parkinson's disease},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {6},
doi = {10.1111/cns.14728}
}
EUVIMED